- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| 12.11.25 | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 207 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11.25 | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10.25 | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09.25 | Summers Value Partners' Update on Journey Medical (DERM) | 6 | Insider Monkey | ||
| 28.08.25 | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08.25 | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08.25 | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08.25 | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08.25 | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 5 | Seeking Alpha | ||
| 12.08.25 | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 591 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,015 | -0,07 % | Ihre wichtigsten Termine: Frische Quartalszahlen von: Pepsico, PayPal, Pfizer, AMD, Merck & Co und KSB | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ELI LILLY | 894,80 | -0,01 % | Abnehmpille schlägt ein: Starker Start ins neue Jahr - Novo Nordisk zeigt Eli Lilly die Rücklichter! | © Foto: Kristian Tuxen Ladegaard Berg - NurPhotoNach einem schwachen Vorjahr meldet sich Novo Nordisk 2026 eindrucksvoll zurück. Die neue Wegovy-Tablette sorgt in den USA für einen starken Marktstart.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 402,50 | -0,45 % | WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and... ► Artikel lesen | |
| EYEPOINT | 11,035 | 0,00 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| JAZZ PHARMACEUTICALS | 139,35 | -0,46 % | Boehringer Ingelheim Limited: Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer | Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients
Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 160,00 | 0,00 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| OPKO HEALTH | 1,046 | 0,00 % | OPKO Health, Inc.: OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism | This is the third program that successfully combines Entera's oral peptide N-Tab- platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim... ► Artikel lesen | |
| UNITED THERAPEUTICS | 410,20 | -0,15 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 37,580 | -0,53 % | Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment | WASHINGTON (dpa-AFX) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| TG THERAPEUTICS | 24,365 | 0,00 % | TG Therapeutics presents BRIUMVI data at ACTRIMS forum | ||
| BRIDGEBIO PHARMA | 57,98 | +0,73 % | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent | ||
| AVADEL PHARMACEUTICALS | 18,100 | 0,00 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,450 | -2,27 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 8,380 Euro und damit +0,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.